Protagenic Therapeutics
Protagenic Therapeutics
PTIX
NASDAQ
0.27
USD
0.00%
About
Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses.
Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels.
In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 7.1K |
| Three Month Average Volume | 169.2K |
| High Low | |
| Fifty-Two Week High | 1.98 USD |
| Fifty-Two Week Low | 0.5 USD |
| Fifty-Two Week High Date | 26 Sep 2023 |
| Fifty-Two Week Low Date | 15 Aug 2024 |
| Price and Volume | |
| Current Price | 0.6062 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -6.71% |
| Thirteen Week Relative Price Change | -57.09% |
| Twenty-Six Week Relative Price Change | -44.87% |
| Fifty-Two Week Relative Price Change | -74.54% |
| Year-to-Date Relative Price Change | -48.29% |
| Price Change | |
| One Day Price Change | 4.10% |
| Thirteen Week Price Change | -54.08% |
| Twenty-Six Week Price Change | -39.39% |
| Five Day Price Change | -6.68% |
| Fifty-Two Week Price Change | -68.09% |
| Year-to-Date Price Change | -38.77% |
| Month-to-Date Price Change | -14.62% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.82706 USD |
| Book Value Per Share (Most Recent Quarter) | 0.17741 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.82706 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.17741 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.36258 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.15097 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.4543 USD |
| Normalized (Last Fiscal Year) | -1.15097 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.15097 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.4543 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.15097 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.4543 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.91452 USD |
| Cash Per Share (Most Recent Quarter) | 0.20697 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.14448 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.44301 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.16007 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -29.46% |
| EPS Change (Trailing Twelve Months) | -82.04% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -924,600 |
| Net Debt (Last Fiscal Year) | -4,056,010 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -3,853,560 |
| Free Cash Flow (Trailing Twelve Months) | -5,105,240 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -10 |
| Net Interest Coverage (Trailing Twelve Months) | -17 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -80.91% |
| Return on Assets (Trailing Twelve Months) | -152.72% |
| Return on Assets (5 Year) | -74.49% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -94.48% |
| Return on Equity (Trailing Twelve Months) | -206.36% |
| Return on Equity (5 Year) | -103.42% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -94.48% |
| Return on Investment (Trailing Twelve Months) | -206.36% |
| Return on Investment (5 Year) | -92.56% |